RetinalGenix Technologies (RTGN) Cash from Operations Growth (1y) (2021 - 2026)
RetinalGenix Technologies (RTGN) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.92 Bn | 146.27 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 119.50 Bn | 116.62 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 102.71 Bn | 94.54 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 69.72 Bn | 68.51 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 49.24 Bn | 45.57 Bn | 1.29 Bn | -84.38% |
| 6 | GE HealthCare Technologies | 29.74 Bn | 27.67 Bn | 1.98 Bn | 16.00% |
| 7 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 8 | Dexcom | 28.96 Bn | 27.84 Bn | 750.30 Mn | 185.96% |
| 9 | Steris | 20.31 Bn | 19.88 Bn | 697.10 Mn | 28.60% |
| 10 | RetinalGenix Technologies | - | - | - | 41.67% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.67% |
| Dec 31, 2025 | 31.21% |
| Sep 30, 2025 | 57.95% |
| Jun 30, 2025 | 3.95% |
| Mar 31, 2025 | -14.29% |
| Dec 31, 2024 | 35.73% |
| Sep 30, 2024 | -721.23% |
| Jun 30, 2024 | -16.95% |
| Mar 31, 2024 | -111.17% |
| Dec 31, 2023 | -772.91% |
| Sep 30, 2023 | 167.42% |
| Jun 30, 2023 | -1,100.41% |
| Mar 31, 2023 | 19.85% |
| Dec 31, 2022 | 88.57% |
| Sep 30, 2022 | 72.28% |
| Jun 30, 2022 | 96.10% |
| Mar 31, 2022 | 75.76% |
| Dec 31, 2021 | 21.82% |